bioAffinity Technologies Teams with American Cancer Society to Raise Funds for Lung Cancer Screening
15 Noviembre 2023 - 7:00AM
Business Wire
bioAffinity Technologies, Inc. (Nasdaq: BIAF;
BIAFW), a biotechnology company focused on the need for
noninvasive, accurate tests for the detection of early-stage cancer
and lung disease, today launched a campaign in partnership with the
American Cancer Society (ACS) to increase lung cancer screening in
Texas.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20231115775728/en/
A partnership to improve lung cancer
screening. (Graphic: Business Wire)
“The Power of Three” campaign emphasizes the importance of
joining forces in the fight against lung cancer by supporting local
programs like the Quality Improvement Program to Increase Lung
Cancer Screening provided by the University of Texas Health Science
Center (UT Health) at San Antonio. The campaign highlights the work
of ACS and UT Health and provides information about bioAffinity
Technologies’ CyPath® Lung, a noninvasive test to improve early
detection of lung cancer.
“Early detection of cancer saves lives, and screening for cancer
– particularly lung cancer – is powerful. We are proud to join
forces with the American Cancer Society and UT Health – thus, the
power of three – to encourage more of our neighbors to be screened
for this deadly cancer which is too often diagnosed at late stage
when treatment options are less effective,” bioAffinity President
and Chief Executive Officer Maria Zannes said. “We want to thank
all donors who go to the ACS website in advance for your generosity
and commitment to saving lives.”
Since launching the program in 2022, ACS has provided funding
and support to UT Health San Antonio primary care centers to
increase lung cancer screening and improve lung nodule management
for its patients. Ramon Cancino, MD, who oversees cancer prevention
and screening activities at UT Health San Antonio, said funding
from the ACS “has created a large ripple effect in UT Health’s
commitment to advance lung cancer screening.”
“bioAffinity Technologies shares our commitment to early
detection and treatment of lung cancer, and we are grateful for the
Company’s support of this successful program,” said Patrick
Isenberg, Director of Corporate Relations for ACS South Region. The
ACS reports that the screening program has increased the percent of
eligible UT Health patients receiving a low dose CT under the U.S.
Preventive Services Task Force recommendations from 7% to 25% at a
time when the statewide rate in Texas is only 2.2%.
About CyPath® Lung
CyPath® Lung uses flow cytometry to identify cell populations in
patient sputum that indicate malignancy. Automated data analysis
developed using proprietary artificial intelligence can help
determine if cancer is present or if the patient is cancer-free.
CyPath® Lung may be used alone or in combination with other
diagnostic tools, providing a clearer picture of the patient’s
condition. CyPath® Lung incorporates a fluorescent porphyrin, TCPP,
that is preferentially taken up by cancer and cancer-related cells.
In a clinical trial, CyPath® Lung showed 92% sensitivity, 87%
specificity and 88% accuracy in detecting lung cancer in patients
at high risk for the disease who had small lung nodules less than
20 millimeters. Half of all patients in the trial who had cancer
were diagnosed in early Stages I or II. Diagnosing and treating
early-stage cancer can increase patient survival and improve
outcomes.
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. addresses the need for
noninvasive diagnosis of early-stage cancer and diseases of the
lung and broad-spectrum cancer treatments. The Company’s first
product, CyPath® Lung, is a noninvasive test that has shown high
sensitivity, specificity and accuracy for the detection of
early-stage lung cancer. CyPath® Lung is marketed as a Laboratory
Developed Test (LDT) by Precision Pathology Laboratory Services, a
subsidiary of bioAffinity Technologies. Research and optimization
of the Company’s platform technologies are conducted in its
laboratories at Precision Pathology and The University of Texas at
San Antonio. For more information, visit www.bioaffinitytech.com
and follow us on LinkedIn, Facebook and X.
Forward-Looking Statements
Certain statements in this press release constitute
"forward-looking statements" within the meaning of the federal
securities laws. Words such as "may," "might," "will," "should,"
"believe," "expect," "anticipate," "estimate," "continue,"
"predict," "forecast," "project," "plan," "intend" or similar
expressions, or statements regarding intent, belief, or current
expectations, are forward-looking statements. These forward-looking
statements are based upon current estimates and assumptions and
include statements regarding plans to increase lung cancer
screening in Texas. These forward-looking statements are subject to
various risks and uncertainties, many of which are difficult to
predict that could cause actual results to differ materially from
current expectations and assumptions from those set forth or
implied by any forward-looking statements. Important factors that
could cause actual results to differ materially from current
expectations include, among others, the ability to increase lung
cancer screening in Texas and the other factors discussed in the
Company’s Annual Report on Form 10-K for the year ended December
31, 2022, and its subsequent filings with the SEC, including
subsequent periodic reports on Forms 10-Q and 8-K. Such
forward-looking statements are based on facts and conditions as
they exist at the time such statements are made and predictions as
to future facts and conditions. While the Company believes these
forward-looking statements are reasonable, readers of this press
release are cautioned not to place undue reliance on any
forward-looking statements. The information in this release is
provided only as of the date of this release, and the Company does
not undertake any obligation to update any forward-looking
statement relating to matters discussed in this press release,
except as may be required by applicable securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231115775728/en/
bioAffinity Technologies Julie Anne Overton Director of
Communications jao@bioaffinitytech.com
Investor Relations Dave Gentry RedChip Companies Inc.
1-800-RED-CHIP (733-2447) or 407-491-4498 BIAF@redchip.com
bioAffinity Technologies (NASDAQ:BIAF)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
bioAffinity Technologies (NASDAQ:BIAF)
Gráfica de Acción Histórica
De May 2023 a May 2024